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Disclaimer:Thisguidelineisdesignedprimarilyasaneducationalresourceformedicalgeneticistsandotherhealthcareproviders
to help them provide quality medical genetic services. Adherence to this guideline does not necessarily assure a successful medical
outcome. This guideline should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and
tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the
geneticistshouldapplyhisorherownprofessionaljudgmenttothespecificclinicalcircumstancespresentedbytheindividualpatient
or specimen. It may be prudent, however, to document in the patient’s record the rationale for any significant deviation from this
guideline.
Osteogenesis imperfecta (OI) is probably the most common
genetic form of fracture predisposition. The term OI encompasses
a broad range of clinical presentations that may be first apparent
from early in pregnancies to late in life, reflecting the extent of
bone deformity and fracture predisposition at different stages of
development or postnatal ages. Depending on the age of presen-
tation, OI can be difficult to distinguish from some other genetic
and nongenetic causes of fractures, including nonaccidental in-
jury (abuse). The strategies for evaluation and the testing dis-
cussed here provide guidelines for evaluation that should help to
distinguish among causes for fracture and bone deformity.
OVERVIEW
Osteogenesis imperfecta (OI) is an inherited disorder of
connective tissue characterized by bone fragility and fractures;
other clinical features include blue sclerae, adult onset hearing
loss and joint laxity.1 The severity ranges from lethal in the
perinatalperiodtooccasionalfracture.Inheritanceisgenerally
autosomal dominant but new mutations are common and re-
cessive inheritance occurs. In most instances (about 90%), a
mutation in one of the two genes (COL1A1 and COL1A2) that
encodethechainsoftypeIcollagen,themajorproteinofbone,
accounts for the phenotype.2 Less frequently, yet-to-be-iden-
tified genes are responsible.3–5 The diagnosis of OI is consid-
ered at different times: during fetal development, at birth, in
childhood, or less often in adults. Regardless of the time at
whichthediagnosisissuspected,thefirstlineofevaluationisa
detailed medical history, family history, physical examination,
appropriateradiographsandroutinelabtesting.Ifthesedonot
lead to diagnosis, then specialized genetic testing is warranted.
We have organized the approach to diagnosis of OI in an age-
specific fashion.
OI: IDENTIFICATION IN PREGNANCY
OI may be suspected in a fetus at different gestational ages,
depending on whether the clinical question is raised by family
history or by routine ultrasound examination.
In the presence of a positive family history of OI
The fetus is usually at a 50% risk for OI when a parent has
OI.WhenonlyasiblinghasOI,theriskvariesfrom0%to50%,
reflecting the proportion of parental gametes that have the
mutation in a mosaic pattern.6 Both targeted ultrasound ex-
aminations and laboratory testing (protein-based or DNA-
based) can be considered.
Fetal Ultrasound Examination: Ultrasound examination,
trans-abdominal (TA) or trans-vaginal (TV)7,8 should be of-
fered as early as 13–14 weeks gestation for a pregnancy at risk
for the severe, lethal form of OI (OI type II) and 16–20 weeks
for one at risk for OI type III. Ultrasound identification of OI
type I and OI type IV has been reported infrequently after 20
weeks gestation on the basis of fetal fracture, but cannot be
relied upon.8 (Table 1, Fig. 1 )
Laboratory Testing
ForthepregnancyatriskformostformsofOI(OItypeII,III
or IV) on the basis of family history, biochemical analysis of
type I collagen synthesized by cultured chorionic villi cells
(CVS) can be offered if collagen screening studies have been
completed on the affected parent or a previous affected infant
andshowntobeabnormal.6ThetimefromCVSbiopsytofinal
diagnosis is about 3–4 weeks. The same biochemical assay can-
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amountsoftypeIprocollagen.Prenataldiagnosisbybiochemical
testing is not available for the identification of OI type I. The
reduced synthesis of type I collagen chains typically seen in
cellsfromindividualswithOItypeIcannotbedetectedreliably
in CVS cells.
MutationanalysiscanbeperformedforalltypesofOI,ifthe
mutation in the family is known, using DNA extracted from
CVS cells or amniocytes. The time from initial tissue sampling
to test result is about 7–14 days.
In routine care of the pregnant woman with a negative
family history of OI
Ultrasound detection of skeletal anomalies may raise the
suspicionofOI.Whenmicromeliaandundermineralizationof
the skeleton are found at 14–16 weeks gestation, the major
differential includes OI type II, achondrogenesis types IA, IB
and II, and autosomal recessive (severe infantile) hypophos-
phatasia (Table 2). In experienced centers, the sonographic
evaluation will generally lead to a specific diagnosis. For most
disorders, the gene(s) in which causative mutations lie are
Fig.1. StrategiesforPrenatalDiagnosis(weeksgestation).FromPepinM,AtkinsonM,StarmanBJ,ByersPH.Strategiesandoutcomesofprenataldiagnosisforosteogenesisimperfecta:
a review of biochemical and molecular studies completed in 129 pregnancies. Prenat Diagn 1997;17:559–570. ©John Wiley & Sons Limited. Reproduced with permission.
Table 1
Ultrasound identification of OI during pregnancy (Listed in order of first ultrasound detection)
Type Genetics Clinical findings Ultrasound findings
First ultrasound
detection
OI II lethal
perinatal
Autosomal
dominant
Lethal perinatal type: Undermineralized skull,
micromelic bones, “beaded” ribs on x-ray,
bone deformity, platyspondyly
Undermineralization, broad, crumpled
and shortened limbs, thin beaded
ribs, fractures, angulation or bowing
of long bones, normal appearing
hands, deformable calvarium
14 wks
OI III Autosomal
dominant
Progressively deforming type: Moderate
deformity of limbs at birth, sclerael hue
varies, very short stature, dentinogenesis
imperfecta (DI)
Thin ribs, short limbs, fractures,
undermineralized skull, long bone
length falls away from normal 16–18
weeks
18 wks
OI IV Autosomal
dominant
Normal sclerae, mild/moderate limb deformity
with fracture, variable short stature,
DI, some hearing loss
Rarely, long bone bowing and/or
fracture
After 20 wks but
not common
OI I Autosomal
dominant
Fractures with little or no limb deformity, blue
sclerae, normal stature, hearing loss, DI
Rarely, long bone bowing or fracture 20 wks but
not common
OI V Autosomal
dominant
Similar to OI IV plus calcification of
interosseous membrane of forearm, radial
head dislocation, hyperplastic callus
formation
Unknown Not described
OI VI Unknown More fractures than OI type IV, vertebral
compression fractures, no DI
Unknown Not described
OI VII Autosomal
recessive
Congenital fractures, blue sclerae, early
deformity of legs, coxa vara, osteopenia
Unknown Not described
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individual, their identification may take several weeks. As a
result, a discussion about pregnancy continuation or termina-
tion generally rests on sonographic evaluation (Table 2).
When termination is performed on the basis of ultrasound
findings, the specific diagnosis, including OI, can be deter-
mined by biochemical study of cultured cells or analysis of
DNA from the fetus. Detailed postmortem evaluation and
x-rays of the fetus are a necessary adjunct to diagnosis. If the
pregnancy is continued to delivery, the genetic evaluation can
be completed in the newborn period.
OI type III is seldom identified before 18 weeks gestation and
confirmation of the diagnosis often requires serial ultrasounds to
track evolving findings. The prenatal phenotype overlaps that of
perinatal hypophosphatasia (frequency of 1/100,000) (Table 3).
OI: IDENTIFICATION IN CHILDHOOD
In infancy and childhood, the clinical examination is the key
first step in evaluation of the child with suspected OI. The evalu-
ationrequiresfamiliaritywiththenaturalhistoryandvariationin
clinical presentation of OI, particularly in the infant or toddler.
Mild forms of OI may go unnoticed by even experienced general
clinicians. Referral to an experienced physician familiar with the
range of clinical expression of OI (such as a medical geneticist) is
relatively inexpensive in comparison to laboratory testing and
may be all that is necessary to secure the diagnosis. There are
severalclinicalcircumstancesthatleadtotheevaluationofachild
for a brittle bone disorder such as OI.
Family history of OI
When a parent or relative is affected, the physical examina-
tion and radiographic findings in the child may be sufficient
for clinical confirmation of OI. Exclusion of the diagnosis may
bemoredifficultinindividualswithmildforms.Iftheinfantor
toddlerhasfeworequivocalfindings,theclinicianmayadopta
wait and watch approach. If the family wishes to pursue pre-
natal diagnosis in a subsequent pregnancy, then laboratory
testing (biochemical or DNA-based testing) is necessary.
Table 3
Ultrasound differential diagnosis at 18–20 weeks gestation
Differential diagnosis Gestational weeks Genetics Characteristics Possible lab testing
OI type III 18–20 wks AD Shortened limbs, thin ribs,
fractures/angulation/bowing
COL1A1/COL1A2
Perinatal/infantile 20 wks AR Profound undermineralization
of skeleton, underossification
of skull and extremities,
deformed limbs
TNSALP mutations
Hypophosphatasia
(1/100,000)
Table 2
Ultrasound differential diagnosis at 16 –18 weeks gestation
Differential diagnosis
Earliest ultrasound
identification Genetics Characteristics Possible lab testing
OI type II lethal type
1/60,000
14–16 wks AD Beaded ribs, micromelic limbs, fractures,
undermineralized skull
COL1A1/COL1A2 mutation
identification
Achondrogenesis type
IB
16 wks AR Short limbs, short ribs, barrel shaped
thorax & irregular scapulae,
undermineralized sacral bones &
skull, short undermineralized
vertebral bodies
Diastrophic dysplasia sulfate
transporter (DTDST)
gene mutation
identification14
Achondrogenesis type
IA
14–16 wks AR Short limbs, short ribs, splayed ends, rib
fractures, undermineralized bones and
skull, bowing, absent ossification of
vertebral bodies & sacrum
Unknown
Achondrogenesis type
II
14–16 wks AD Extreme micromelia, barrel shaped
thorax, undermineralized skull,
bowing, absent ossification vertebral
bodies & sacrum
COL2A1 mutation
identification15
Perinatal/infantile
Hypophosphatasia
(1/100,000)
14–16 wks AR Profound undermineralization of
skeleton, underossification of skull
and extremities, deformed limbs
TNSALP mutations16
Thamatrophoric
sydplasia (1/30,000)
16 wks AD Very short limgs, “telephone receiver
femurs.” Normal mineralzation,
small chest
FGFR3 mutations17
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At birth, OI types II and III are generally recognized on
clinical and radiologic grounds and the clinical diagnosis is
usually unequivocal.1 Genetic evaluation and counseling is
recommended for confirmation and discussion about natural
history, treatment and prenatal diagnosis in future pregnan-
cies.
In childhood, in the absence of a positive family history,
mostchildrennewlydiagnosedwithOIareidentifiedafterone
or more fractures. The severity of the phenotype varies from
the progressive deforming type (OI type III) to the mild phe-
notypeofOItypeI(seeTable3).Thedifferentialdiagnosisfor
frequent fracture in childhood is relatively limited and in-
cludes both inherited and acquired conditions. Hypophos-
phatasia, osteopetrosis with renal tubular acidosis, hypophos-
phatemicosteomalacia(rickets)andnonaccidentalinjuryshould
be considered.
Short stature, blue sclerae and dentinogenesis
imperfecta (DI)
Sometimes, the evaluation for OI in childhood is prompted
by recognition of blue sclerae, conductive hearing loss, denti-
nogenesis imperfecta (DI) or during an evaluation for short
stature. Blue sclerae are present in all children with OI type I
and are, at times, dramatic. Roughly 20% of families with OI
Table 4
Clinical presentation and Genetic differential diagnosis of fractures in childhood
Type Inheritance Clinical phenotype Test
OI type II AD Lethal perinatal, undermineralized skull, beaded
ribs, compressed femurs, long bone
deformity, platyspondyly
Biochemical or Molecular
OI type III AD/AR Progressively deforming bones, moderate
deformity at birth, sclerae hue varies, very
short stature, DI
Biochemical or Molecular
OI type I AD Fracture with little or no deformity, blue sclerae,
normal stature, hearing loss
Biochemical or Molecular
OI type IV AD Normal scleare, mild/moderate bone deformity
with fracture, variable short stature, DI, some
hearing loss
Biochemical or Molecular
OI type V AD Similar to OI IV plus calcification of
interosseous membrane of forearm, radial
head dislocation, hyperplastic callus
formation
Unknown
OI type VI AD or AR More fractures than OI IV, vertebral
compression fractures, no DI
Unknown
OI type VII AR Congenital fractures, blue sclerae, early
deformity of lower extremities,
coxa vara, osteopenia
Unknown
Hypophosphatasia, perinatal
and infantile form
(1/100,000)
AR Severe undermineralization, bone deformity,
fractures
TNSALP mutations
Hypophosphatasia
(childhood type)
AD/AR Premature loss of teeth, rachitic bone changes,
fracture, undermineralization of bones
Urinary
phosphoethanolamine,
plasma plasma ALP,
TNSALPL gene testing
Juvenile Paget’s disease AR rapidly remodeling bone, osteopenia, fractures,
progressive skeletal deformity
TNFRSF11B mutations18
Bruck syndrome AR Osteoporosis, joint contractures and fractures
and short stature
PLOD2 mutations19–21
Osteopetrosis with renal
tubular acidosis
AR Before 2 years of age, fractures, short stature
and delayed development. RTA, cerebral
calcifications, mental retardation and dental
malocclusion
CAII mutations22
Hypophosphatemic
osteomalacia “rickets”
AD, XLD Before 2, osteomalacia and poor growth.
Later hypophosphatemia
Lowserumphosphorus,
elevatedalk.phosphatase,
lowurinecalcium
FGF23, HYP genes23
Non-accidental injury - Unexplained fractures in infancy
Byers et al.
386 Genetics IN Medicinetype I have DI. Infants and toddlers with OI type IV may have
light blue sclerae and usually have DI, which may be subtle.
Some children may be identified by short stature as about a
third of individuals with OI type IV are less than the third
percent for height in childhood (Table 4).9
The infant or toddler with “unexplained fractures”
Inthefirstyearoflife,thepresenceoffracturesforwhichan
explanationisnotprovidedorforwhichthestatedmechanism
of injury is not consistent with the fracture type raises a con-
cern for nonaccidental injury (NAI). As NAI is the leading
cause of fractures in infancy, a child abuse evaluation is war-
ranted in such circumstances (http://nccanch.acf.hhs.gov/). If
a biological basis for brittle bones is suspected and clinical ex-
amination is not definitive, then laboratory testing for OI and
select metabolic bone disorders is generally appropriate.
On clinical examination, if an infant with unexplained frac-
tures has few features of OI, as may be the case with OI type I,
IV, V and VI, it may be difficult to confirm or exclude the
diagnosis on the basis of family history, history and physical
examination alone, particularly in the 0–8 months age group.
SomeclinicalfeaturesofOIoverlapwithnormalfindingsin
infancy. For example: blue sclerae occur in normal infants be-
fore12monthsofage.However,withappropriateclinicaleval-
uation,thediagnosesofOItypeIandIIIarerarelyinquestion.
Infants with OI type IV, V and VI, with normal sclerae and
normallength,maypresentonlywithfracture.InfantswithOI
can be missed on clinical evaluation and declared victims of
NAI based on radiographic findings alone.10,11 Biochemical or
DNAdiagnostictesting,thoughnot100%sensitive,maybethe
best way to attempt to guard against these rare outcomes.10,11
When the index of clinical suspicion of OI is high, the physi-
cian may feel compelled to request testing to provide labora-
tory confirmation of the diagnosis in order to curtail addi-
tional Child Protective Services referrals.
Thefirststudies10evaluatingtheusefulnessandsensitivityof
collagenscreeningforidentificationofOIinchildrenwithun-
explainedfracturessuggestedthatthephysicalexaminationby
a clinician familiar with OI was as sensitive as biochemical
diagnostic testing for identifying the child with OI. A recent
review of biochemical testing completed on cells from 262 in-
fants with OI versus infants with unexplained fractures de-
scribed 3 children who were not identified as affected by com-
prehensive clinical evaluation in whom a type I collagen
abnormalitywasdetectedonbiochemicaltesting.Thecollagen
abnormality identified in each instance was characteristic for
OI – two with OI type I and one with OI type IV The clinical
findings of thethree infants in whom the clinical diagnosis of OI
was not made could not be distinguished clinically from those
whowerepositivelyidentifiedbyclinicalexamination.Theexper-
tise of the clinician and absence of any clinical findings were not
contributing factors.11 Thus, in instances when the clinical diag-
nosis of OI is not apparent and the only feature of NAI present is
unexplained fractures, lab testing may be the best way to provide
the child and family with all possible safeguards.
LABORATORY TESTING FOR OI
Laboratory diagnosis of OI depends on the determination
that cultured fibroblasts make either less type I procollagen
than normal, make abnormal type I procollagen molecules or
the identification of a mutation in COL1A1 or COL1A2, the
two genes that encode the chains of type I procollagen. Colla-
gen screening and DNA-based testing are available at the Uni-
versityofWashington(www.pathology.washington.edu/clinical/
collagen) and DNA-based testing is available at the Tulane Uni-
versityMatrixDNADiagnosticLab(http://www.som.tulane.edu/
gene_therapy/matrix/matrix_dna_diagnostics.shtml).Testsensi-
tivity is high for both types of tests but it is not clear if the
sensitivityisadditive.12,13MutationsinCOL1A1andCOL1A2do
not cause OI type V, VI or VII, which account for about 8% of all
children with OI.
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